Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Ledger.
Press releases published on April 25, 2025
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
GlobeNewswire
·
April 25, 2025
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical …
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
GlobeNewswire
·
April 25, 2025
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational study Company remains confident in continuing to pursue evorpacept in …
Rush Factory Oyj: Osakevaihdon odotetaan toteutuvan arviolta 28.4.2025 ja kaupankäynnin alkavan arviolta 29.4.2025; päivitys hallituksen kokoonpanoon osakevaihdon jälkeen
GlobeNewswire
·
April 25, 2025
Rush Factory Oyj 25.4.2025 klo 15.30 EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA …
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
GlobeNewswire
·
April 25, 2025
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a …
Directorate change
GlobeNewswire
·
April 25, 2025
Directorate Change Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce the appointment of Mr. Colm Howlin as an Executive Director of the Company …
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 25, 2025
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected …